



## Understanding the impact of cancer diagnosis and treatment on everyday life

## **12 MONTH BREAST CANCER CRF**

## FOR STAFF USE ONLY

## **CRF** Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copy of the 6 month CRF when completing this 12 month CRF: please complete any additional treatment details that were not captured at 6 months (for example, additional treatments, or end dates of those ongoing at 6 months)
- If you have any queries, please contact the HORIZONS
  Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID		]/	]/				]	
Participant's date of birt	:h	d d	m	m	У	У	У	У

Has the participant been tested for BRCA1 or BRCA2 (please tick one box)

Yes (already recorded in previous CRF)	
Yes (but not recorded in previous CRF)	
No	
Unknown	

If you answered "Yes (but not recorded in previous CRF)" to the above question, was the result (please tick one box)

Positive for a mutation in BRCA1 or BRCA2	
Negative for a mutation in BRCA1 or BRCA2	
Ambiguous or uncertain	
Unknown	
Awaiting result	

Has the participant had any other genetic tests for inherited cancers? (please tick one box)

Yes (already recorded in previous CRF)	
Yes (but not recorded in previous CRF)	
No	
Unknown	

If you answered "Yes (but not recorded in previous CRF)" to the above question, please provide some information about the participant's other genetic test(s) by completing the table(s) overleaf

	/		
--	---	--	--

Name of genetic test for cancer (1)	Result of genetic test
	Positive
	Negative
	Ambiguous/uncertain
	Awaiting result
	Unknown

Name of genetic test for cancer (2)	Result of genetic test
	Positive
	Negative
	Ambiguous/uncertain
	Awaiting result
	Unknown

Has the participant developed any NEW co-morbidities (which were not recorded in the baseline or 6 month CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	

Participant's Study ID		/	/			
------------------------	--	---	---	--	--	--

Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	
Clinical diagnosis of depression	
Other Psychiatric Diagnosis (eg. schizophrenia, bipolar disorder etc.)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	
Other (please give details)	
Other (please give details)	

Partici	pant's	Study	ID



What treatments has the participant received **since those captured at 6 months**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing at 6 months (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has received	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treatment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Surgery	Wide local excision (breast conserving surgery)		// 20		
	Mastectomy		// 20		
	Sentinel node biopsy (SNBx)		// 20		
	Axillary node clearance (ANC)		// 20		
	Other axillary treatment please describe on line below)		// 20		
Breast Reconstruction	Immediate reconstruction		//20		
	Delayed reconstruction		// 20		
	Delayed reconstruction is planned but has not yet taken place				
Reconstruction Type	Implant		//20		
	Latissimus dorsi (LAD)		// 20		
	Deep inferior epigastric perforator artery (DIEP)		//20		
	Tissue reconstruction with abdominal tissue (TRAM)		// 20		
	Nipple reconstruction		// 20		
	Nipple/Areola Tattoo		// 20		
	Other (please describe on line below)		//20		

Participant's Study ID	/	

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why				
Radiotherapy	Breast		// 20	// 20					
	Chest wall		// 20	// 20					
	Supraclavicular fossa (SCF)		// 20	// 20					
	Axilla		// 20	//20					
	Number of radiotherapy fractions, please enter on line								
	Total radiotherapy dose please enter on line								
Chemotherapy	Drug(s), please give details below		// 20	// 20					
	Chemotherapy number of	cycles, ple	ase enter on line	I					
Ovarian Suppression	Medical, please give details below		//20	//20					
	Surgical		//20						
	Radiotherapy		//20	// 20					

Participant's	Study ID		/		
Treatment type	Specific treatment details	Tick if patient has received	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treatment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Hormone	Tamoxifen		// 20	_/_/20	
Therapy					
	Anastrazole		// 20	// 20	
	Letrozole		//20	// 20	
	Exemestane		//20	// 20	
	Other, please give details below		// 20	// 20	
	Were bisphosphonates give Yes No Unknov		ick)?		
Symmeterisation Operations	Contralateral risk reducing mastectomy		// 20	//20	
	Other symmeterisation operation (please give details)		// 20	//20	
	Other risk reducing sur- gery (please give details)		//20	//20	
Immunotherapy	Trastuzumab (Herceptin)		//20	//20	
	Pertuzumab (Perjeta)		// 20	_/_/20	
	Other immunotherapy (please give details		//20	// 20	
Additional Treatment	If any additional treatment has been given please describe		// 20	// 20	

Participant's Study ID		/	/			
------------------------	--	---	---	--	--	--

Has the participant had a **local** recurrence of their breast cancer? (please tick one box)

Unknown

If the participant has had a local recurrence, on what date was the recurrence

diagnosed?			
alagnosea.	d	d	m

Yes



No

Since the participant's diagnosis of breast cancer, has there been any evidence of distant metastatic disease? (please tick one box)

Yes	No	Unknown	

If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:

dd mm v v v v
---------------

Please provide details of the site(s) of distant metastatic disease:

Is the participant pre or post menopause? (please tick one box)

Pre menopause	
Post menopause	
Unknown	

Participant's S	tudy II		/		]/[			
Is the participant taking part in a clinical trial? (please tick one box)								
	Yes			No			Unknown	

If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in

Name of clinical trial \_\_\_\_\_

Since the participant's diagnosis of breast cancer, have they been diagnosed with another new primary cancer? (please tick one box)

If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table below

Type of cancer	
Date of diagnosis	//20
Treatment received	
Date treatment ended (if finished)	/ / 20

What type of follow-up care is the participant receiving? (please tick ONE box)

Routine/regular hospital clinic based follow-up (medical or nurse led,	
face-to-face or by telephone)	
Primary care based follow-up	
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)	
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?	

Participant's Study ID



Has the participant been referred to any of the following services and/or had a Holistic Needs Assessment? (please tick all that apply)

Participant has been referred to palliative care services	
Participant has been referred to psychological services	
If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)	
Participant has been referred to community services	
Participant has been referred for treatment related problems (e.g. pain clinic)	
If ticked, please provide more details below:	
Participant has had an HNA (holistic needs assessment)	

If the participant has died please give the date and cause of death:

Participant's date of death

							_		
d	d		m	m		17	17	17	17
u	u				/	У	У	У	У
		-							

Cause of participant's death

Cause of death not known

1) a)	
1) b)	
1) c)	
2)	

Please add your name and signature and the date that you completed this CRF
---

Name	Signature	Signature				
Date CRF completed	d d <b>/</b> m m <b>/</b> y y y					